Concepts (284)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Pneumococcal Vaccines | 7 | 2019 | 571 | 1.16 | Why? |
| Meningococcal Vaccines | 5 | 2019 | 225 | 1.05 | Why? |
| Meningococcal Infections | 5 | 2019 | 216 | 1.03 | Why? |
| England | 32 | 2021 | 5116 | 1.00 | Why? |
| Vaccines, Conjugate | 4 | 2019 | 328 | 0.98 | Why? |
| Vaccines, Attenuated | 7 | 2020 | 952 | 0.91 | Why? |
| Heptavalent Pneumococcal Conjugate Vaccine | 3 | 2019 | 64 | 0.83 | Why? |
| Vaccines, Combined | 1 | 2019 | 67 | 0.77 | Why? |
| Measles-Mumps-Rubella Vaccine | 2 | 2019 | 282 | 0.75 | Why? |
| Rotavirus Vaccines | 2 | 2020 | 203 | 0.71 | Why? |
| Pneumococcal Infections | 6 | 2021 | 562 | 0.71 | Why? |
| Papillomavirus Vaccines | 3 | 2019 | 405 | 0.69 | Why? |
| Computer Systems | 2 | 2021 | 255 | 0.67 | Why? |
| Influenza Vaccines | 10 | 2020 | 2941 | 0.63 | Why? |
| Rotavirus Infections | 2 | 2020 | 355 | 0.63 | Why? |
| Immunization Schedule | 8 | 2021 | 1305 | 0.60 | Why? |
| Product Surveillance, Postmarketing | 1 | 2017 | 189 | 0.58 | Why? |
| Vaccines, Inactivated | 2 | 2019 | 1562 | 0.57 | Why? |
| Influenza A Virus, H1N1 Subtype | 7 | 2020 | 2984 | 0.55 | Why? |
| Immunization Programs | 10 | 2019 | 2006 | 0.54 | Why? |
| Streptococcus pneumoniae | 7 | 2021 | 827 | 0.54 | Why? |
| Vaccination | 19 | 2021 | 19050 | 0.53 | Why? |
| Pertussis Vaccine | 3 | 2018 | 89 | 0.50 | Why? |
| Hepatitis E virus | 1 | 2017 | 306 | 0.50 | Why? |
| Adverse Drug Reaction Reporting Systems | 1 | 2017 | 694 | 0.48 | Why? |
| Influenza, Human | 12 | 2021 | 10779 | 0.48 | Why? |
| Hepatitis E | 1 | 2017 | 319 | 0.47 | Why? |
| Influenza B virus | 4 | 2019 | 815 | 0.46 | Why? |
| Gastroenteritis | 1 | 2016 | 489 | 0.45 | Why? |
| Whooping Cough | 3 | 2018 | 201 | 0.45 | Why? |
| Vaccine Potency | 5 | 2021 | 339 | 0.43 | Why? |
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 2 | 2019 | 31 | 0.37 | Why? |
| Guillain-Barre Syndrome | 3 | 2017 | 1495 | 0.34 | Why? |
| Blood Transfusion | 1 | 2017 | 1399 | 0.33 | Why? |
| Influenza A Virus, H3N2 Subtype | 3 | 2020 | 572 | 0.31 | Why? |
| Genotype | 2 | 2019 | 4697 | 0.30 | Why? |
| Electronic Health Records | 2 | 2021 | 3492 | 0.29 | Why? |
| Antibodies, Bacterial | 3 | 2018 | 510 | 0.28 | Why? |
| Infant | 20 | 2021 | 30274 | 0.26 | Why? |
| Neisseria meningitidis, Serogroup C | 2 | 2019 | 46 | 0.26 | Why? |
| Child, Preschool | 23 | 2021 | 36283 | 0.26 | Why? |
| Immunization, Secondary | 5 | 2018 | 1649 | 0.24 | Why? |
| Serogroup | 3 | 2019 | 510 | 0.24 | Why? |
| Child | 27 | 2021 | 70012 | 0.22 | Why? |
| Seasons | 6 | 2020 | 4071 | 0.21 | Why? |
| Adolescent | 26 | 2021 | 86841 | 0.21 | Why? |
| Models, Biological | 2 | 2018 | 4907 | 0.21 | Why? |
| Carcinoma, Lewis Lung | 1 | 2018 | 4 | 0.20 | Why? |
| United Kingdom | 15 | 2021 | 18046 | 0.20 | Why? |
| Streptococcal Vaccines | 1 | 2019 | 31 | 0.20 | Why? |
| Prosencephalon | 1 | 2018 | 13 | 0.19 | Why? |
| Organogenesis | 1 | 2018 | 24 | 0.19 | Why? |
| Poisson Distribution | 1 | 2020 | 348 | 0.19 | Why? |
| Clostridium tetani | 1 | 2018 | 9 | 0.19 | Why? |
| Stillbirth | 2 | 2021 | 544 | 0.19 | Why? |
| Intussusception | 1 | 2020 | 102 | 0.19 | Why? |
| Neuralgia, Postherpetic | 1 | 2017 | 22 | 0.18 | Why? |
| Medical Records Systems, Computerized | 1 | 2020 | 159 | 0.18 | Why? |
| Chlamydia trachomatis | 1 | 2019 | 172 | 0.18 | Why? |
| Blastocyst | 1 | 2018 | 65 | 0.18 | Why? |
| Varicella Zoster Virus Infection | 1 | 2018 | 40 | 0.18 | Why? |
| Mumps | 1 | 2019 | 110 | 0.18 | Why? |
| Cause of Death | 3 | 2021 | 4823 | 0.17 | Why? |
| Bordetella pertussis | 1 | 2018 | 117 | 0.17 | Why? |
| Rubella | 1 | 2019 | 127 | 0.17 | Why? |
| Female | 47 | 2021 | 380317 | 0.17 | Why? |
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2018 | 92 | 0.17 | Why? |
| Neisseria meningitidis, Serogroup B | 1 | 2018 | 66 | 0.17 | Why? |
| Infant, Newborn, Diseases | 2 | 2019 | 394 | 0.17 | Why? |
| Meningitis, Meningococcal | 1 | 2019 | 114 | 0.17 | Why? |
| Seizures, Febrile | 1 | 2017 | 59 | 0.17 | Why? |
| Disease Outbreaks | 6 | 2021 | 27595 | 0.16 | Why? |
| Rotavirus | 1 | 2020 | 329 | 0.16 | Why? |
| Otitis Media | 1 | 2018 | 106 | 0.16 | Why? |
| Chlamydia Infections | 1 | 2019 | 248 | 0.16 | Why? |
| Measles virus | 1 | 2018 | 194 | 0.16 | Why? |
| Astrocytes | 1 | 2018 | 298 | 0.16 | Why? |
| Herpes Zoster Vaccine | 1 | 2017 | 112 | 0.16 | Why? |
| Male | 42 | 2021 | 367725 | 0.16 | Why? |
| Case-Control Studies | 7 | 2021 | 17671 | 0.16 | Why? |
| Rabies Vaccines | 1 | 2016 | 106 | 0.15 | Why? |
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2016 | 91 | 0.15 | Why? |
| Immunogenicity, Vaccine | 2 | 2021 | 4624 | 0.15 | Why? |
| Family Health | 1 | 2021 | 731 | 0.15 | Why? |
| Herpesvirus 3, Human | 1 | 2018 | 228 | 0.15 | Why? |
| Streptococcal Infections | 1 | 2019 | 255 | 0.15 | Why? |
| Extremities | 1 | 2016 | 179 | 0.15 | Why? |
| Humans | 66 | 2021 | 930598 | 0.15 | Why? |
| Neisseria meningitidis | 1 | 2017 | 229 | 0.15 | Why? |
| Hospitalization | 6 | 2021 | 54280 | 0.15 | Why? |
| Rabies | 1 | 2016 | 113 | 0.14 | Why? |
| Neuraminidase | 1 | 2017 | 289 | 0.14 | Why? |
| Measles Vaccine | 1 | 2018 | 301 | 0.14 | Why? |
| Pneumonia, Pneumococcal | 1 | 2018 | 251 | 0.14 | Why? |
| Measles | 2 | 2019 | 608 | 0.14 | Why? |
| Young Adult | 18 | 2021 | 93724 | 0.14 | Why? |
| Meat | 1 | 2017 | 380 | 0.13 | Why? |
| Disease Notification | 1 | 2020 | 639 | 0.13 | Why? |
| Age Distribution | 2 | 2020 | 3567 | 0.13 | Why? |
| London | 4 | 2021 | 2166 | 0.13 | Why? |
| Edema | 1 | 2016 | 333 | 0.13 | Why? |
| Epidemiological Monitoring | 3 | 2021 | 3493 | 0.13 | Why? |
| Aged, 80 and over | 14 | 2021 | 88759 | 0.12 | Why? |
| Incidence | 10 | 2021 | 25622 | 0.12 | Why? |
| Herpes Zoster | 1 | 2017 | 331 | 0.12 | Why? |
| Infant, Newborn | 9 | 2021 | 23105 | 0.12 | Why? |
| Infant, Premature | 1 | 2017 | 883 | 0.12 | Why? |
| Sentinel Surveillance | 4 | 2020 | 1093 | 0.11 | Why? |
| Coinfection | 2 | 2021 | 6820 | 0.11 | Why? |
| Ebolavirus | 1 | 2018 | 834 | 0.11 | Why? |
| Papillomavirus Infections | 1 | 2019 | 861 | 0.10 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 1261 | 0.10 | Why? |
| Aged | 20 | 2021 | 215776 | 0.10 | Why? |
| Respiratory Tract Infections | 3 | 2021 | 6817 | 0.10 | Why? |
| Seroepidemiologic Studies | 6 | 2021 | 10017 | 0.10 | Why? |
| Adult | 25 | 2021 | 244371 | 0.10 | Why? |
| Clinical Protocols | 1 | 2021 | 2734 | 0.10 | Why? |
| Viremia | 1 | 2017 | 1020 | 0.10 | Why? |
| Risk | 2 | 2021 | 5288 | 0.09 | Why? |
| Splenectomy | 1 | 2009 | 85 | 0.09 | Why? |
| Seizures | 1 | 2017 | 1163 | 0.09 | Why? |
| Health Care Costs | 1 | 2016 | 1007 | 0.09 | Why? |
| Blood Donors | 2 | 2021 | 2956 | 0.09 | Why? |
| Swine | 1 | 2017 | 3352 | 0.09 | Why? |
| Schools | 2 | 2021 | 4187 | 0.09 | Why? |
| Middle Aged | 18 | 2021 | 270681 | 0.08 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2016 | 1138 | 0.08 | Why? |
| Health Status | 1 | 2021 | 3259 | 0.08 | Why? |
| Prenatal Care | 1 | 2017 | 1314 | 0.08 | Why? |
| Mortality | 2 | 2021 | 7132 | 0.08 | Why? |
| Mothers | 1 | 2017 | 1624 | 0.08 | Why? |
| RNA, Messenger | 1 | 2021 | 5131 | 0.08 | Why? |
| Hemorrhagic Fever, Ebola | 1 | 2018 | 1475 | 0.08 | Why? |
| Enzyme Inhibitors | 1 | 2017 | 1881 | 0.08 | Why? |
| Public Health Surveillance | 1 | 2020 | 3129 | 0.08 | Why? |
| Carrier State | 1 | 2018 | 2100 | 0.08 | Why? |
| World Health Organization | 1 | 2019 | 4213 | 0.08 | Why? |
| Occupational Diseases | 1 | 2021 | 2787 | 0.07 | Why? |
| Population Surveillance | 5 | 2021 | 4967 | 0.07 | Why? |
| Influenza A virus | 1 | 2017 | 2234 | 0.07 | Why? |
| Cohort Studies | 5 | 2021 | 36005 | 0.07 | Why? |
| Single-Blind Method | 2 | 2021 | 1283 | 0.07 | Why? |
| Genetic Variation | 1 | 2019 | 3919 | 0.07 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2019 | 3388 | 0.07 | Why? |
| Wales | 2 | 2018 | 758 | 0.07 | Why? |
| Primary Health Care | 3 | 2019 | 4839 | 0.07 | Why? |
| Antibodies, Viral | 8 | 2021 | 51949 | 0.07 | Why? |
| Public Health | 8 | 2021 | 16359 | 0.07 | Why? |
| Laboratories | 1 | 2017 | 2858 | 0.07 | Why? |
| Algorithms | 1 | 2020 | 7346 | 0.06 | Why? |
| Pregnancy | 7 | 2021 | 23879 | 0.06 | Why? |
| Antibodies, Neutralizing | 3 | 2019 | 25288 | 0.06 | Why? |
| Occupational Exposure | 1 | 2021 | 4742 | 0.06 | Why? |
| Age Factors | 6 | 2021 | 21039 | 0.06 | Why? |
| Pregnancy Complications, Infectious | 2 | 2019 | 11559 | 0.06 | Why? |
| Treatment Outcome | 8 | 2021 | 51732 | 0.06 | Why? |
| Risk Factors | 7 | 2021 | 71621 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Prospective Studies | 6 | 2021 | 43301 | 0.06 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.06 | Why? |
| Equivalence Trials as Topic | 1 | 2021 | 242 | 0.05 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.05 | Why? |
| Sepsis | 1 | 2018 | 3517 | 0.05 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.05 | Why? |
| Emergency Medical Services | 1 | 2016 | 3557 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Intention to Treat Analysis | 1 | 2021 | 673 | 0.05 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.05 | Why? |
| Genetic Complementation Test | 1 | 2018 | 59 | 0.05 | Why? |
| Mouse Embryonic Stem Cells | 1 | 2018 | 17 | 0.05 | Why? |
| Neocortex | 1 | 2018 | 17 | 0.05 | Why? |
| Mass Screening | 1 | 2019 | 8005 | 0.05 | Why? |
| Mass Vaccination | 1 | 2009 | 1101 | 0.05 | Why? |
| Program Evaluation | 2 | 2017 | 1929 | 0.05 | Why? |
| Chimera | 1 | 2018 | 83 | 0.05 | Why? |
| Family Characteristics | 2 | 2021 | 2551 | 0.05 | Why? |
| Germ Cells | 1 | 2018 | 39 | 0.05 | Why? |
| Nasopharynx | 1 | 2018 | 10224 | 0.05 | Why? |
| Preliminary Data | 1 | 2020 | 457 | 0.05 | Why? |
| Immunization | 2 | 2018 | 2019 | 0.05 | Why? |
| Hemagglutination Inhibition Tests | 1 | 2018 | 191 | 0.04 | Why? |
| Neuropeptides | 1 | 2018 | 91 | 0.04 | Why? |
| Streptococcus agalactiae | 1 | 2019 | 194 | 0.04 | Why? |
| Tetanus | 1 | 2018 | 61 | 0.04 | Why? |
| Serotyping | 1 | 2017 | 154 | 0.04 | Why? |
| Memory | 1 | 2018 | 137 | 0.04 | Why? |
| Serbia | 1 | 2018 | 227 | 0.04 | Why? |
| Sierra Leone | 1 | 2018 | 267 | 0.04 | Why? |
| Lethargy | 1 | 2016 | 55 | 0.04 | Why? |
| Microtubule-Associated Proteins | 1 | 2018 | 187 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Maternal-Fetal Exchange | 1 | 2018 | 209 | 0.04 | Why? |
| Prevalence | 4 | 2021 | 25773 | 0.04 | Why? |
| Injections, Intradermal | 1 | 2016 | 102 | 0.04 | Why? |
| Capillary Permeability | 1 | 2018 | 277 | 0.04 | Why? |
| Motor Activity | 1 | 2018 | 217 | 0.04 | Why? |
| Poliovirus Vaccine, Inactivated | 1 | 2016 | 72 | 0.04 | Why? |
| Cross Protection | 1 | 2019 | 373 | 0.04 | Why? |
| Health Personnel | 3 | 2021 | 29646 | 0.04 | Why? |
| Meningitis | 1 | 2018 | 163 | 0.04 | Why? |
| Hippocampus | 1 | 2018 | 237 | 0.04 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.04 | Why? |
| Multimorbidity | 1 | 2021 | 703 | 0.04 | Why? |
| DNA-Binding Proteins | 1 | 2018 | 469 | 0.04 | Why? |
| Poverty Areas | 1 | 2020 | 556 | 0.04 | Why? |
| Risk Assessment | 2 | 2017 | 25439 | 0.04 | Why? |
| Papillomaviridae | 1 | 2019 | 404 | 0.03 | Why? |
| Time Factors | 4 | 2019 | 31397 | 0.03 | Why? |
| Maternal Health | 1 | 2019 | 331 | 0.03 | Why? |
| Blood-Brain Barrier | 1 | 2018 | 531 | 0.03 | Why? |
| Uganda | 1 | 2018 | 1057 | 0.03 | Why? |
| Depression | 1 | 2018 | 14116 | 0.03 | Why? |
| False Positive Reactions | 1 | 2019 | 1338 | 0.03 | Why? |
| Immunoglobulin G | 4 | 2021 | 21571 | 0.03 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.03 | Why? |
| Animals | 3 | 2018 | 78931 | 0.03 | Why? |
| Comorbidity | 1 | 2018 | 34796 | 0.03 | Why? |
| Europe | 2 | 2021 | 12702 | 0.03 | Why? |
| Health Services Accessibility | 1 | 2017 | 10697 | 0.03 | Why? |
| Cluster Analysis | 1 | 2021 | 3001 | 0.03 | Why? |
| Fibrinogen | 1 | 2018 | 1048 | 0.03 | Why? |
| Bias | 1 | 2018 | 1109 | 0.03 | Why? |
| Endemic Diseases | 1 | 2016 | 480 | 0.03 | Why? |
| Neurons | 1 | 2018 | 864 | 0.03 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.03 | Why? |
| Mice, Transgenic | 1 | 2018 | 2739 | 0.03 | Why? |
| Sex Factors | 2 | 2020 | 11014 | 0.03 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.03 | Why? |
| History, 21st Century | 1 | 2017 | 1849 | 0.02 | Why? |
| South Africa | 1 | 2020 | 3326 | 0.02 | Why? |
| Cell Line, Tumor | 1 | 2018 | 3608 | 0.02 | Why? |
| Urban Population | 1 | 2020 | 2000 | 0.02 | Why? |
| Drug Approval | 1 | 2019 | 1325 | 0.02 | Why? |
| Regression Analysis | 1 | 2017 | 2484 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2019 | 2259 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2020 | 5440 | 0.02 | Why? |
| Obstetric Labor, Premature | 1 | 2009 | 114 | 0.02 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.02 | Why? |
| Pain | 1 | 2016 | 1084 | 0.02 | Why? |
| Neuritis | 1 | 2009 | 109 | 0.02 | Why? |
| Endothelial Cells | 1 | 2018 | 2048 | 0.02 | Why? |
| Optic Neuritis | 1 | 2009 | 132 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Rural Population | 1 | 2020 | 2408 | 0.02 | Why? |
| Health Care Surveys | 1 | 2017 | 2942 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.02 | Why? |
| Premature Birth | 1 | 2019 | 2151 | 0.02 | Why? |
| State Medicine | 1 | 2021 | 2847 | 0.02 | Why? |
| Convalescence | 1 | 2018 | 2829 | 0.02 | Why? |
| Smoking | 1 | 2020 | 3358 | 0.02 | Why? |
| Myelitis, Transverse | 1 | 2009 | 218 | 0.02 | Why? |
| Chronic Disease | 1 | 2021 | 5139 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Universities | 1 | 2021 | 4374 | 0.02 | Why? |
| Renal Insufficiency, Chronic | 1 | 2020 | 2654 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Diarrhea | 1 | 2016 | 2743 | 0.02 | Why? |
| Neutralization Tests | 1 | 2018 | 6698 | 0.02 | Why? |
| Outpatients | 1 | 2017 | 3417 | 0.02 | Why? |
| Antiviral Agents | 1 | 2017 | 41703 | 0.02 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.02 | Why? |
| Students | 1 | 2021 | 5255 | 0.02 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.01 | Why? |
| Communicable Disease Control | 2 | 2021 | 29620 | 0.01 | Why? |
| Retrospective Studies | 3 | 2020 | 105322 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Models, Statistical | 1 | 2018 | 5312 | 0.01 | Why? |
| Interleukin-6 | 1 | 2018 | 7522 | 0.01 | Why? |
| Ambulatory Care | 1 | 2017 | 4947 | 0.01 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Travel | 1 | 2016 | 7220 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 13720 | 0.01 | Why? |
| Immunity, Herd | 1 | 2004 | 1011 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.01 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.01 | Why? |
| Multiple Sclerosis | 1 | 2009 | 2600 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 7868 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| Anxiety | 1 | 2018 | 17311 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2004 | 17020 | 0.00 | Why? |